Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

4.00

Today's Change

-0.22 (5.21%)

Day's Change

4.00 - 4.35

Trading Volume

1,529,801

Profile
CU6

Exchange:  Australian Securities Exchange Australian Securities Exchange

Currency:  AUD AUD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Ms. Michelle Parker Ms. Michelle Parker

Full Time Employees:  50 50

IPO Date:  2021-08-25 2021-08-25

CIK: 

ISIN:  AU0000165375 AU0000165375

CUSIP: 

Beta:  1.68 1.68

Last Dividend:  0.00 0.00

Dcf Diff:  5.90 5.90

Dcf:  -1.90 -1.90

Description

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Address

National Innovation Centre,
Sydney, NSW 2015, AU

61 2 9209 4037

http://www.claritypharmaceuticals.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment